NCT00714688 - A Study to Evaluate Effectiveness and Safety of Prolonged Release OROS Methylphenidate in Adults With Attention Deficit Hyperactivity Disorder | Biotech Hunter

Enrollment

279

Participants

Timeline

Start Date

February 29, 2008

Primary Completion Date

April 30, 2009

Study Completion Date

April 30, 2009

Conditions

Attention Deficit/ Hyperactivity Disorder

Interventions

DRUG

prolonged release (PR) OROS methylphenidate 54 mg

18+36mg once daily for 13 weeks

DRUG

prolonged release (PR) OROS methylphenidate 72 mg

2x36mg once daily for 13 weeks

DRUG

Placebo

2xplacebo once daily for 13 weeks

Trial Locations (42)

Unknown

Antwerp

Brussels

Kortenberg

Mechelen

Mons

Aarhus

Hjørring

Holstebro

Helsinki

Oulu

Pori

Montpellier

Nice

Paris

Ahrensburg

Aschaffenburg

Berlin

Düsseldorf

Essen

Freiburg im Breisgau

Mannheim

München

Saarbrücken

Würzburg

Nijmegen

The Hague

Bryne

Oslo

Ottestad

Skien

Barcelona

Madrid

Huddinge

Linköping

Lund

Malmo

Örebro

Uppsala

Basel Bs

Zurich

Cambridge

Swansea